Nature, Published online: 19 March 2025; doi:10.1038/s41586-025-08717-5

Results of a multicentre phase 1 clinical trial evaluating treatment with the engineered herpes simplex virus VG161 in advanced liver cancer indicate a good safety profile and promising efficacy.